Showing results (61-70 of 6,003) with videos related to
Sort By:
Pageof 601
Molecular Cancer Therapeutics|January 22, 2011
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsTsuyoshi Minematsu, Kathleen M GiacominiMolecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.Molecular Cancer Therapeutics|January 11, 2011
Antisense inhibition of survivin expression as a cancer therapeuticRosa A Carrasco, Nancy B Stamm, Eric Marcusson, et al.Molecular Cancer Therapeutics|January 13, 2011
ORAI1-mediated calcium influx in lactation and in breast cancerDamara McAndrew, Desma M Grice, Amelia A Peters, et al.Molecular Cancer Therapeutics|October 14, 2010
Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeuticsKristi E Allen, Glen J WeissMolecular Cancer Therapeutics|September 23, 2010
Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destructionTatsuo Okui, Tsuyoshi Shimo, Takuya Fukazawa, et al.Molecular Cancer Therapeutics|March 12, 2011
CCN1, a candidate target for zoledronic acid treatment in breast cancerIngrid Espinoza, Hong Liu, Robert Busby, et al.Molecular Cancer Therapeutics|March 12, 2011
Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2AKuen-Feng Chen, Hui-Chuan Yu, Chun-Yu Liu, et al.Molecular Cancer Therapeutics|April 8, 2011
The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathwayJenny E Hernandez-Davies, Joan P Zape, Elliot M Landaw, et al.Molecular Cancer Therapeutics|April 9, 2011
Targeting oncogenic ALK: a promising strategy for cancer treatmentEnrique Grande, María-Victoria Bolós, Edurne ArriolaPageof 601